Long-term denosumab therapy for osteoporosis and its interruption: expert opinion of the Society for Metabolic Bone Diseases working group within the Czech Medical Association of J.E. Purkyně
Clinical Osteology · 2018
DOI: 10.36290/clo.2018.007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Osteology, 2018. Verfasst von Milan Bayer und 8 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Bayer, M., Horák, P., Palička, V., Pavelka, K., Pikner, R., Jan, R., Šenk, F., Vyskočil, V., & Zikán, V. (2018). Long-term denosumab therapy for osteoporosis and its interruption: expert opinion of the Society for Metabolic Bone Diseases working group within the Czech Medical Association of J.E. Purkyně. Clinical Osteology. https://doi.org/10.36290/clo.2018.007
Vancouver
Bayer M, Horák P, Palička V, Pavelka K, Pikner R, Jan R, et al. Long-term denosumab therapy for osteoporosis and its interruption: expert opinion of the Society for Metabolic Bone Diseases working group within the Czech Medical Association of J.E. Purkyně. Clinical Osteology. 2018. doi:10.36290/clo.2018.007
BibTeX
@article{Bayer2018,
author = {Bayer, Milan and Horák, Pavel and Palička, Vladimír and Pavelka, Karel and Pikner, Richard and Jan, Rosa and Šenk, František and Vyskočil, Václav and Zikán, Vít},
title = {Long-term denosumab therapy for osteoporosis and its interruption: expert opinion of the Society for Metabolic Bone Diseases working group within the Czech Medical Association of J.E. Purkyně},
journal = {Clinical Osteology},
year = {2018},
doi = {10.36290/clo.2018.007}
}
EUVIMED